Recent Updates
Recently added Catalysts
TLX Negative Sentiment

TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights

Key Takeaway: A class action lawsuit has been initiated against Telix Pharmaceuticals Limited, alleging that the company made false statements regarding its progress on prostate cancer therapies. The lawsuit claims that Telix overstated its supply chain quality and failed to disclose significant risks associated with its operations. Investors who purchased shares between February 21, 2025, and August 28, 2025, are being encouraged to discuss their legal rights with the law firm Bragar Eagel & Squire. The deadline for investors to apply to be lead plaintiffs is January 9, 2026.
Price reaction · baseline $7.63 (2026-01-08 close) · hit after-hours · 3 other TLX headline(s) in the window, move may be shared
day 0 close
-0.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Telix Pharmaceuticals Limited.
  • Allegations include false and misleading statements about prostate cancer therapeutic candidates.
  • Defendants reportedly overstated the quality of Telix’s supply chain.
  • Investors suffered damages when true information became public.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Telix securities between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) in the United States District Court for the Southern District of Indiana on behalf of all persons and entities who purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”).
Investors have until January 9, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Frequently Asked Questions

Who can join the Telix class action lawsuit?

Anyone who purchased Telix securities between February 21, 2025, and August 28, 2025.

What should I do if I suffered losses from Telix securities?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire directly.

When is the deadline to apply as lead plaintiff?

Investors must apply by January 9, 2026, to be considered for lead plaintiff.

What allegations are made against Telix in the lawsuit?

The lawsuit claims Telix overstated cancer therapy progress and supply chain quality.

How can I contact Bragar Eagel & Squire for more information?

You can email investigations@bespc.com or call (212) 355-4648 for details.

Last updated: Jan 9, 2026